{"originalText": "缘于入院前5月因诊为降结肠癌伴肝转移，于2016.01.15、2016.02.05在我院予“奥沙利铂200MGIVGTTD1+卡培他滨片(希罗达)1500MGBIDPOD1-14”方案行术前新辅助化疗，未见明显化疗后不良反应，于2016年02月29日于我院行腹腔镜上右半结肠切除术（姑息性），术顺，术后病理回报（201605763）：结肠隆起型黏液腺癌，侵及浆膜上层，侵犯脉管组织，未见肯定神经侵犯。手术标本远、近切端均未见癌浸润。找到肠周淋巴结4/22个，见癌转移。肠周脂肪中找到4枚癌结节。肠粘膜溃疡。另送（右结肠动脉根部）、（肠系膜上静脉根部）镜上为纤维、血管及脂肪组织。术后恢复可，无腹痛、腹胀，无恶心、呕吐等不适，术后予“盐酸伊立替康240MG静滴D1+卡培他滨片1500MGBIDPOD1-14”“盐酸伊立替康240MG静滴D1+安维汀400MG（自备）D1+替吉奥60MGBIDPOD1-14”方案化疗3次，化疗期间予制酸、补液、营养支持等对症处理。为进一步治疗，门诊拟“降结肠癌伴肝转移（PT1N2AM1AIVA期）”收入院，自下次出院以来，精神、睡眠、饮食可，大小便如常，体重未见明显减轻。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 10, "end_pos": 18}, {"end_pos": 50, "label_type": "药物", "overlap": 0, "start_pos": 46}, {"end_pos": 68, "label_type": "药物", "overlap": 0, "start_pos": 63}, {"end_pos": 72, "label_type": "药物", "overlap": 0, "start_pos": 69}, {"end_pos": 140, "label_type": "手术", "overlap": 0, "start_pos": 129}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 167, "end_pos": 176}, {"end_pos": 223, "label_type": "解剖部位", "overlap": 0, "start_pos": 218}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 234, "end_pos": 235}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 247, "end_pos": 248}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 256, "end_pos": 259}, {"label_type": "解剖部位", "overlap": 0, "start_pos": 266, "end_pos": 267}, {"end_pos": 297, "label_type": "解剖部位", "overlap": 0, "start_pos": 296}, {"end_pos": 300, "label_type": "解剖部位", "overlap": 0, "start_pos": 299}, {"end_pos": 322, "label_type": "药物", "overlap": 0, "start_pos": 316}, {"end_pos": 337, "label_type": "药物", "overlap": 0, "start_pos": 332}, {"end_pos": 361, "label_type": "药物", "overlap": 0, "start_pos": 355}, {"end_pos": 374, "label_type": "药物", "overlap": 0, "start_pos": 371}, {"end_pos": 389, "label_type": "药物", "overlap": 0, "start_pos": 386}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 443, "end_pos": 451}]}
